Clinical Trials Directory

Trials / Completed

CompletedNCT00000291

Effects of Labetalol on Human Cocaine Use - 8

Effects of Labetalol on Human Cocaine Use

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
0 (planned)
Sponsor
National Institute on Drug Abuse (NIDA) · NIH
Sex
All
Age
20 Years – 45 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine the effect of labetalol treatment on the subjective and physiological effects of cocaine.

Detailed description

The goal of this study was to investigate the safety and utility of labetalol an alpha and beta adrenergic block, for cocaine dependence in humans. A total of 12 subjects were enrolled in this double blind, placebo controlled outpatient study. After baseline measures are obtained, three experimental sessions were held at least 2 days apart. Subjects were administered a single low (100 mg) or high dose of labetalol (200mg) or placebo on each of 3 experimental sessions. The labetalol doses were given in ascending order and the placebo treatment were randomly inserted into the sequence. A single dose of smoked cocaine (0.4 mg/kg) was administered 2 hrs after labetalol or placebo treatment. During the sessions, several subjective, behavioral and physiological measures were obtained.

Conditions

Interventions

TypeNameDescription
DRUGLabetalol

Timeline

Start date
1997-10-01
Completion
2001-12-01
First posted
1999-09-21
Last updated
2017-01-12

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00000291. Inclusion in this directory is not an endorsement.